Septerna reports Q3 2026 results, SEP-204 named lead TSHR candidate
Phase 1 data for hypoparathyroidism candidate SEP-479 are expected in Q1 2027, the same quarter Septerna plans to start a Phase 1 trial of new candidate SEP-204.
SEC filing
2 stories
Phase 1 data for hypoparathyroidism candidate SEP-479 are expected in Q1 2027, the same quarter Septerna plans to start a Phase 1 trial of new candidate SEP-204.
SEC filing
The company reported preclinical data at the 2026 American Thyroid Association meeting and plans to start a Phase 1 trial in the first quarter of 2027.
SEC filing